PIN9 BUDGET IMPACT MODEL OF ABACAVIR/LAMIVUDINE FOR TREATMENT OF HIV INFECTED PATIENTS IN MEXICO  by Rely, K. et al.
genders across years, ranging from 13.3 cases/100,000 person years in females in
2005 to 13.7 cases/100,000 person years in males in 2007. In 2005 and 2006 the
highest incidence was seen in 45 to 54 year olds. In 2007 and 2008 the highest
incidence was in 55 to 64 year olds. Hepatitis A incidence was highest in the West
census regions for each year from 2005-2008. CONCLUSIONS: In a large commer-
cially insured population,we observed similar hepatitis A incidence rates formales
and females across all years examined. Incidence was highest in 45 – 54 and 55 – 64
year olds. The West region had the highest incidence. No evidence of a decline in
incidence presented across the years examined. These results are in line with the
fact that hepatitis A vaccination rates remain low, despite the availability of effec-
tive hepatitis A vaccines, and the increased number of patient populations in
whom hepatitis A vaccination is recommended.
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OBJECTIVES: HIV impairs immune and nervous systems of the individuals and
with progression through different stages, the patients develop a spectrum of neu-
rological complications directly or indirectly related to the viral infection. Since the
introduction of highly active anti-retroviral therapy (HAART), HIV has evolved into
a chronic condition resulting in considerable change in the epidemiology of neu-
rological complications. The objective of the study was to identify and summarize
the incidence and prevalence of neuropathy among HIV positive patients and
subgroups. METHODS: A systematic search of the literature was performed using
MEDLINE® and EMBASE®. The relevant literature was identified based on pre-
defined criteria. Prevalence data were collected from cross-sectional and cohort
studies. Incidence data were collected from cohort and case-control studies.
RESULTS: Thirty-seven studies were included of which there were 23 cohort stud-
ies, 13 cross-sectional studies and 1 case-control study. The prevalence of neurop-
athy among HIV patients derived from 25 studies varied from 1.2% up to 69.4%.
Regarding the development of neuropathy among HIV positive patients, standard-
ized by study duration, the rates per 100 person-years ranged from 0.7 to 39.7.
Among older patients there is a greater risk of neuropathy. The same seems the
case for patients with more severe disease. The association of HIV treatment with
neuropathy is less clear. CONCLUSIONS: Currently available studies providing in-
formation on the incidence and prevalence of neuropathy among HIV patients
suggests a significant burden, but there is a great variation in results across studies.
There is no definitive explanation for the variation however, it underscores the fact
that complexity of the disease, along with absence of standardized diagnostic cri-
teria has considerably influenced the methodologies and outcomes of the studies.
Standardization of an approach to HIV related neuropathy may enhance future
research, allowing for a broader understanding of the condition and its associated
burden.
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OBJECTIVES: Methicillin-resistant Staphylococcus aureus (MRSA) is a gram-positive
bacteria that are resistant to certain -lactam antibiotics and are known as emerg-
ing cause for skin and soft tissue infection. To validate the CDC definition with
antibiotic susceptibility pattern and to identify if any novel risk factors for MRSA
infection are present in the Midwestern population. METHODS: A cross sectional
study was conducted at the academic health care center. Medical records for 100
patients from The Nebraska Medical Center (TNMC) from January 1, 2009 through
December 31, 2009 were collected. MRSA positive patients were investigated and
categorized as hospital-acquired MRSA (HA MRSA) or community- acquired MRSA
(CA MRSA) on the basis of CDC definition. RESULTS: From total 100 MRSA cases of
2009, eighty six percent were HA MRSA and 14% were CA MRSA. Specimen source
(P-value 0.003), race (P-value 0.01), number of present illness (P-value 0.01), and
number of past medical history (P-value 0.005), showed a significant difference
between the twoMRSA. Seventy six percent agreement between the CDCdefinition
and the antibiotic susceptibility definition for CA MRSA and HAMRSA using cipro-
floxacin susceptibility was seen. Multivariate logistic regression concluded that
race (OR 3.76 95% CI - 1.04-14.28), specimen source (OR 0.21 95% CI - 0.03-0.85)
and no. of present illnesses (OR 0.49 95% CI – 0.25-0.86) are the predictors for
MRSA infection in the Midwest. CONCLUSIONS: MRSA infection is a health care-
associated public health problem. Identification of risk factors at early stage can
reduce the negative health outcome, further transmissions, and also help in effi-
cient prevention of this disease. Treatment patterns should be changed depending
on the susceptibility pattern of the organism. Research is needed to identify proper
treatment regimens for the Midwestern population.
Infection – Cost Studies
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OBJECTIVES: To calculate the impact of abacavir/lamivudine on the Mexican drug
budget in 2010 and to forecast its impact over the following 5 years. METHODS: A
budget impact model (BIM) of HIV infected patients was developed to evaluate the
costs of abacavir/lamivudina versus emtricitabina/tenofovir and lamivudina/zid-
ovudine from the Mexican Health Care perspective. The BIM was calculated by
triangulating information derived frommultiple Mexican data sources. The model
is based on disease prevalence, drug acquisition cost and sales forecasting data
specific to Mexico. The projected population and incidence of VIH was obtained
from the literature. The (BIM)was based on two scenarios reflecting different levels
of growth in the number of patient. The study was conducted from the Mexican
Healthcare perspective. The average budget impact in the first 5 years (startup
phase) and subsequent years (steady state) was assessed in US dollars. Future costs
were discounted at 5% per recommendations for analyses in Mexico. RESULTS:
Increasing utilization of abacavir/lamivudine, from 5% to 60% over 5 years period
resulted in an net cost saving during the initial startup phase of $ 24millions and $
157 millions to the steady state. These reductions translated to a total net cost
saving of $ 437 millions “in 2010 dollars” over 5 years. The total direct costs de-
creased progressively at the end of the five-year period due to decreased acquisi-
tion drug costs. Sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values of the model parameters.
CONCLUSIONS: The budget impact analysis of abacavir/lamivudine for HIV start-
ing in 2010 shows a positive impact on the health budget because it saves costs
after 2010 and produces a net benefit from the beginning of treatment. Abacavir/
lamivudina led to important cost savings due to its lower drug acquisition cost.
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OBJECTIVES: To design an economic cost comparison model of daptomycin, com-
pared with standard therapy (based on vancomycin) in the treatment of bactere-
mia due to Staphylococcus aureus (both methicillin-resistant and non-resistant
strains) in Colombia.METHODS:We designed a decision tree model (TreeAge soft-
ware) based on one large randomized non-inferiority clinical trial (Fowler, N Engl
J Med, 2006), applying local (direct) costs obtained from a university hospital in
Bogota. We used third party payer perspective; timeframe 6 weeks from the end of
antibiotic therapy. We separately estimated antibiotic costs, hospitalization costs,
“other” hospital costs (which include non-antibiotic drugs, lab tests, medical im-
aging,medical visits, etc.) and total costs. Exchange rate: 1934 Colombian pesos per
US$ (as of July, 2010). RESULTS: When antibiotic costs are considered separately,
thesewere higher in the daptomycin branch (US$3821 vs. US$3366). This difference
disappears when total costs are calculated (US$9317 vs. US$9492). Hospitalization
costs were US$1701 for daptomycin and US$1783 for standard therapy, while
“other” costs were US$3795 and US$4343, respectively. On the other hand, dapto-
mycin therapy is associated with a lower incidence of acute renal failure (NNT 
17). CONCLUSIONS: If the two therapies compared have similar effectiveness, at
similar costs, the discriminating factor in medical decision making should be
safety. Choosing daptomycin instead of standard care (vancomycin) in adult pa-
tient with bacteremia due to S. aureus makes clinical and economic sense.
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OBJECTIVES: Extended intramammary treatment of bovine clinical mastitis (CM)
results in better cure rates but should be balanced economically against higher
drug costs and extra waste of saleablemilk because of a longermilk discard period.
This study aimed to compare licensed extended treatment with pirlimycin (5 infu-
sions q.d.) to shorter licensed treatments with cephapirin (2 infusions b.i.d.) and
hetacillin (3 infusions q.d.) in dairy cows with CM caused by gram-positive patho-
gens (gramCM), accounting for approximately 28% of all bovine mastitis cases in
the US.METHODS:Adecision treewas developed inMS Excel, considering first and
recurrent CM episodes, culling and death of dairy cows with gramCM over an
entire lactation period of 305 days. The model considered costs and losses associ-
atedwith CM and its treatment, culling or deaths aswell as income generated from
saleable milk production and sold cows. Prices and cost data were compiled from
public sources (US-2010, perspective of the producer); efficacy data were derived
from published studies. All input parameters were varied extensively in one-way
sensitivity analyses. RESULTS: Per treated cow, the income frommilk production
over one lactation period was $3051.72 (pirlimycin), $3054.66 (cephapirin), and
$3049.21 (hetacillin). Costs associated with the disease and treatment totaled to
$226.78 (pirlimycin), $236.84 (cephapirin), and $238.34 (hetacillin). As such, ex-
tended treatment with pirlimycin results in a higher profit margin of $7.12 and
$14.07 per treated cow and per lactation, compared to 2 to 3 infusions with
cephapirin and hetacillin, respectively. Fewer deaths or culling occurred with
pirlimycin. Outcomes were most sensitive to cure rates of first mastitis
episodes. CONCLUSIONS: With US 2010 cost/price data, the economic drawbacks
of extendedmastitis treatment weremore than offset by better efficacy with 5-day
pirlimycin treatment compared to 2 to 3 infusions with cephapirin or hetacillin.
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